var,trl_lbl,data_lvl,lvls,measure,res
trials,Dipeptidyl peptidase 4 (DPP-4) inhibitors,agg,,count,237
trials,Dipeptidyl peptidase 4 (DPP-4) inhibitors,ipd,,count,43
trials,Glucagon-like peptide-1 (GLP-1) analogues,agg,,count,158
trials,Glucagon-like peptide-1 (GLP-1) analogues,ipd,,count,34
trials,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,agg,,count,140
trials,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,ipd,,count,32
trials,Total trials,agg,,count,489
trials,Total trials,ipd,,count,103
arms,Dipeptidyl peptidase 4 (DPP-4) inhibitors,agg,2,count,204
arms,Dipeptidyl peptidase 4 (DPP-4) inhibitors,agg,3,count,25
arms,Dipeptidyl peptidase 4 (DPP-4) inhibitors,agg,4 or 5,count,8
arms,Dipeptidyl peptidase 4 (DPP-4) inhibitors,ipd,2,count,27
arms,Dipeptidyl peptidase 4 (DPP-4) inhibitors,ipd,3,count,10
arms,Dipeptidyl peptidase 4 (DPP-4) inhibitors,ipd,4 or 5,count,6
arms,Glucagon-like peptide-1 (GLP-1) analogues,agg,2,count,106
arms,Glucagon-like peptide-1 (GLP-1) analogues,agg,3,count,41
arms,Glucagon-like peptide-1 (GLP-1) analogues,agg,4 or 5,count,11
arms,Glucagon-like peptide-1 (GLP-1) analogues,ipd,2,count,22
arms,Glucagon-like peptide-1 (GLP-1) analogues,ipd,3,count,9
arms,Glucagon-like peptide-1 (GLP-1) analogues,ipd,4 or 5,count,3
arms,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,agg,2,count,107
arms,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,agg,3,count,28
arms,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,agg,4 or 5,count,5
arms,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,ipd,2,count,12
arms,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,ipd,3,count,16
arms,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,ipd,4 or 5,count,4
arms,Total trials,agg,2,count,388
arms,Total trials,agg,3,count,80
arms,Total trials,agg,4 or 5,count,21
arms,Total trials,ipd,2,count,56
arms,Total trials,ipd,3,count,34
arms,Total trials,ipd,4 or 5,count,13
male,Dipeptidyl peptidase 4 (DPP-4) inhibitors,agg,,count,63066
male,Dipeptidyl peptidase 4 (DPP-4) inhibitors,ipd,,count,16724
male,Glucagon-like peptide-1 (GLP-1) analogues,agg,,count,44780
male,Glucagon-like peptide-1 (GLP-1) analogues,ipd,,count,16309
male,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,agg,,count,24776
male,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,ipd,,count,24638
male,Total trials,agg,,count,124159
male,Total trials,ipd,,count,54465
participants,Dipeptidyl peptidase 4 (DPP-4) inhibitors,agg,,count,109293
participants,Dipeptidyl peptidase 4 (DPP-4) inhibitors,ipd,,count,29991
participants,Glucagon-like peptide-1 (GLP-1) analogues,agg,,count,79184
participants,Glucagon-like peptide-1 (GLP-1) analogues,ipd,,count,28137
participants,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,agg,,count,44039
participants,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,ipd,,count,40191
participants,Total trials,agg,,count,217321
participants,Total trials,ipd,,count,92182
male,Dipeptidyl peptidase 4 (DPP-4) inhibitors,agg,,percent,57.7
male,Dipeptidyl peptidase 4 (DPP-4) inhibitors,ipd,,percent,55.8
male,Glucagon-like peptide-1 (GLP-1) analogues,agg,,percent,56.6
male,Glucagon-like peptide-1 (GLP-1) analogues,ipd,,percent,58
male,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,agg,,percent,56.3
male,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,ipd,,percent,61.3
male,Total trials,agg,,percent,57.1
male,Total trials,ipd,,percent,59.1
age,Dipeptidyl peptidase 4 (DPP-4) inhibitors,agg,,n,109293
age,Dipeptidyl peptidase 4 (DPP-4) inhibitors,ipd,,n,29991
age,Glucagon-like peptide-1 (GLP-1) analogues,agg,,n,79184
age,Glucagon-like peptide-1 (GLP-1) analogues,ipd,,n,28137
age,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,agg,,n,44039
age,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,ipd,,n,40191
age,Total trials,agg,,n,217321
age,Total trials,ipd,,n,92182
age,Dipeptidyl peptidase 4 (DPP-4) inhibitors,agg,,m,58.76639992160106
age,Dipeptidyl peptidase 4 (DPP-4) inhibitors,ipd,,m,57.187192132010935
age,Glucagon-like peptide-1 (GLP-1) analogues,agg,,m,57.91283023164669
age,Glucagon-like peptide-1 (GLP-1) analogues,ipd,,m,59.31373747416614
age,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,agg,,m,61.357848139162385
age,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,ipd,,m,57.78121392019019
age,Total trials,agg,,m,59.12469981025299
age,Total trials,ipd,,m,58.251460707966835
age,Dipeptidyl peptidase 4 (DPP-4) inhibitors,agg,,s,10.785615811087142
age,Dipeptidyl peptidase 4 (DPP-4) inhibitors,ipd,,s,11.23868299066923
age,Glucagon-like peptide-1 (GLP-1) analogues,agg,,s,10.356179617934853
age,Glucagon-like peptide-1 (GLP-1) analogues,ipd,,s,11.009739748351548
age,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,agg,,s,10.732558889873934
age,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,ipd,,s,11.17884548230425
age,Total trials,agg,,s,10.688756828791794
age,Total trials,ipd,,s,11.165489036562317
age,Dipeptidyl peptidase 4 (DPP-4) inhibitors,agg,,q05,40.275001766970725
age,Dipeptidyl peptidase 4 (DPP-4) inhibitors,ipd,,q05,36.86845451272705
age,Glucagon-like peptide-1 (GLP-1) analogues,agg,,q05,40.38363145828527
age,Glucagon-like peptide-1 (GLP-1) analogues,ipd,,q05,40.01701227778733
age,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,agg,,q05,42.91247049201136
age,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,ipd,,q05,36.412194053096925
age,Total trials,agg,,q05,40.874372307595834
age,Total trials,ipd,,q05,37.58243162037424
age,Dipeptidyl peptidase 4 (DPP-4) inhibitors,agg,,q95,75.67834241739334
age,Dipeptidyl peptidase 4 (DPP-4) inhibitors,ipd,,q95,75.06821560835834
age,Glucagon-like peptide-1 (GLP-1) analogues,agg,,q95,74.26659737974805
age,Glucagon-like peptide-1 (GLP-1) analogues,ipd,,q95,76.06795889104069
age,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,agg,,q95,78.22346119641571
age,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,ipd,,q95,75.2293439605906
age,Total trials,agg,,q95,75.95288422161752
age,Total trials,ipd,,q95,75.57129103257911
duration,Dipeptidyl peptidase 4 (DPP-4) inhibitors,agg,,m,30.91983122362869
duration,Dipeptidyl peptidase 4 (DPP-4) inhibitors,ipd,,m,31.599999999999998
duration,Glucagon-like peptide-1 (GLP-1) analogues,agg,,m,32.18143459915612
duration,Glucagon-like peptide-1 (GLP-1) analogues,ipd,,m,31.54901960784314
duration,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,agg,,m,26.5
duration,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,ipd,,m,56.825
duration,Total trials,agg,,m,30.698023176550784
duration,Total trials,ipd,,m,38.658899676375405
duration,Dipeptidyl peptidase 4 (DPP-4) inhibitors,agg,,med,24
duration,Dipeptidyl peptidase 4 (DPP-4) inhibitors,ipd,,med,24
duration,Glucagon-like peptide-1 (GLP-1) analogues,agg,,med,26
duration,Glucagon-like peptide-1 (GLP-1) analogues,ipd,,med,26
duration,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,agg,,med,24
duration,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,ipd,,med,25
duration,Total trials,agg,,med,24
duration,Total trials,ipd,,med,24
duration,Dipeptidyl peptidase 4 (DPP-4) inhibitors,agg,,q05,12
duration,Dipeptidyl peptidase 4 (DPP-4) inhibitors,ipd,,q05,12.2
duration,Glucagon-like peptide-1 (GLP-1) analogues,agg,,q05,12
duration,Glucagon-like peptide-1 (GLP-1) analogues,ipd,,q05,24
duration,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,agg,,q05,12
duration,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,ipd,,q05,17.1
duration,Total trials,agg,,q05,12
duration,Total trials,ipd,,q05,14.200000000000001
duration,Dipeptidyl peptidase 4 (DPP-4) inhibitors,agg,,q95,54.39999999999998
duration,Dipeptidyl peptidase 4 (DPP-4) inhibitors,ipd,,q95,53.8
duration,Glucagon-like peptide-1 (GLP-1) analogues,agg,,q95,56
duration,Glucagon-like peptide-1 (GLP-1) analogues,ipd,,q95,52
duration,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,agg,,q95,52
duration,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,ipd,,q95,239.2
duration,Total trials,agg,,q95,56
duration,Total trials,ipd,,q95,104
